Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 1/Phase 2Diagnosis: Solid Tumor/Phase INCT ID: NCT02079740
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-505
This phase Ib/II trial studies the side effects and best dose of trametinib and navitoclax in treating patients with solid tumors that have spread to other places in the body or cannot be cured or controlled with treatment. Trametinib and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conducting Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute
Overall PI: Ryan Corcoran, M,D, Ph.D,
Massachusetts General Hospital
Contacts: Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100